Ambeed.cn

首页 / / / / Nalidixic acid

Nalidixic acid {[allProObj[0].p_purity_real_show]}

货号:A821895 同义名: 萘啶酸 / NSC 82174;WIN 18,320

Nalidixic acid, synthetic 1,8-naphthyridine, is a spectrum antimicrobial agent.

Nalidixic acid 化学结构 CAS号:389-08-2
Nalidixic acid 化学结构
CAS号:389-08-2
Nalidixic acid 3D分子结构
CAS号:389-08-2
Nalidixic acid 化学结构 CAS号:389-08-2
Nalidixic acid 3D分子结构 CAS号:389-08-2
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Nalidixic acid 纯度/质量文件 产品仅供科研

货号:A821895 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 Topo I Topo II Topo IV Topoisomerase 其他靶点 纯度
Ellagic acid 98%
β-Lapachone 99%+
(s)-10-hydroxycamptothecin 98+%
Camptothecin ++

Topo I, IC50: 0.68 μM

98%
Betulinic acid ++

Eukaryotic topoisomerase I, IC50: 5 μM

98%
Topotecan ++++

Topo I (DU-145 Luc cells), IC50: 2 nM

Topo I (MCF-7 Luc cells), IC50: 13 nM

98%
Irinotecan HCl Trihydrate 98%
SN-38 98%
Levofloxacin hydrate 98%
Dexrazoxane 99%+
Ofloxacin 98+%
Enoxacin 99%+
Flumequine +

Topo II, IC50: 15 μM

98%
Levofloxacin 97%
Etoposide 98%
Pefloxacin mesylate dihydrate 99+%
Marbofloxacin 98+%
Voreloxin HCl 98%
Mitoxantrone dihydrochloride PKC 98%
Nalidixic acid 98%
Doxorubicin 98%
Novobiocin sodium 95%
Amonafide 99%+
Pirarubicin 98%+
Idarubicin HCl +++

Topo II (MCF-7 cells), IC50: 3.3 ng/mL

99%+
Genistein EGFR 98%
Teniposide 98%
Moxifloxacin 98%
Ciprofloxacin 98%
Clinafloxacin 97%
Gatifloxacin 98%
Daunorubicin HCl +++

DNA synthesis, Ki: 20 nM

98%
Epirubicin HCl 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Nalidixic acid 生物活性

靶点
  • Topo II

描述 Nalidixic acid, synthetic 1,8-naphthyridine, is a spectrum antimicrobial agent. Nalidixic acid is against a variety of microorganisms, it is against with Escherichia coli, Pasteurella spp., Klebsiella pneuiiioniae, Aerobacter aeroyenes, Proteus spp., Salmonella spp., Shigella spp. and Brucella spp. with MIC values of 5.0-12.5 μg/ml, 0.5-2.5 μg/ml, 0.8-25.0 μg/ml, 1.0-25.0 μg/ml, 1.25-30.0 μg/ml, 8-3.2 μg/ml, and 7.5-10.0 μg/ml, respectively. The in vivo activity of Nalidixic acid is most pronounced against Gram-negative bacteria, while Gram-positive organisms are generally more resistant. Maximal activity is observed against systemic infections caused by E. coli, A. aerobacter, Proteus mirabilis, Shigella fkxneri, the ED50 values are 25 mg/kg, 60 mg/kg, 50 mg/kg, and 62 mg/kg, respectively. The acute toxicity (LD50) of Nalidixic acid in mice following oral and parenteral administration is: oral, 3300 mg/kg; intravenous, 176 mg/kg, and subcutaneous, 500 mg/kg[2]. The MIC of nalidixic acid was 700 μg/mL against P. aeruginosa. The exposure of P. aeruginosa to different concentrations of nalidixic acid resulted in deformation of most of the growing cells. At the concentration of 600 μg/mL most of the cells turned into elongated and adhere to each other while some of the cells were bulged. The intensity of protein bands were changed when they exposed to nalidixic acid[3]. The combinations of nalidixic acid + methyl gallate/carvacrol improved nalidixic acid resistant pathogenic bacteria inhibition with synergy or partial synergy activity[4].

Nalidixic acid 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02099240 Osteomyelitis Early Phase 1 Recruiting September 2019 United States, Kentucky ... 展开 >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD 收起 <<
NCT03190421 Urinary Tract Infections Not Applicable Recruiting December 30, 2019 United States, Illinois ... 展开 >> Loyola University Medical Center Recruiting Maywood, Illinois, United States, 60153 Contact: Mary J Tulke, RN    708-216-2067    mtulke@luc.edu 收起 <<

Nalidixic acid 参考文献

[1]Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother. 2003 May;51 Suppl 1:13-20.

[2]Crumplin GC, Smith JT. Nalidixic acid: an antibacterial paradox. Antimicrob Agents Chemother. 1975 Sep;8(3):251-61

[3]Al Bahry S, Sivakumar N, Al-Khambashi M. Effect of nalidixic acid on the morphology and protein expression of Pseudomonas aeruginosa. Asian Pac J Trop Med. 2012 Apr;5(4):265-9

[4]Choi JG, Kang OH, Lee YS, Oh YC, Chae HS, Jang HJ, Shin DW, Kwon DY. Antibacterial activity of methyl gallate isolated from Galla Rhois or carvacrol combined with nalidixic acid against nalidixic acid resistant bacteria. Molecules. 2009 May 11;14(5):1773-80

Nalidixic acid 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.31mL

0.86mL

0.43mL

21.53mL

4.31mL

2.15mL

43.06mL

8.61mL

4.31mL

Nalidixic acid 技术信息

CAS号389-08-2
分子式C12H12N2O3
分子量 232.235
别名 萘啶酸 ;NSC 82174;WIN 18,320;Nalidixic Acid, Nevigramon, Neggram, Wintomylon, WIN 18,320
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,Room temperature

溶解度

DMSO: 5 mg/mL(21.53 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 5 mg/mL(21.53 mM),配合低频超声,并水浴加热至45℃助溶

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。